Home
>
US Stocks
>
Global Blood Therapeutics Inc.
Global Blood Therapeutics Inc.
GBT

Global Blood Therapeutics Inc. (GBT)

$30.852.28%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
$31.65
Today Low/High
$30.76 / $32.04
52 Week Low/High
$25.11 / $63.03
Market Cap
$1.97B

Company Details

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Organisation
Global Blood Therapeutics Inc.
Headquaters
South San Francisco, California, US
Employees
389
Industry
Health Technology
CEO
Ted Love

Discover more

Frequently Asked Questions

What is Global Blood Therapeutics Inc. (GBT) share price today?

Can Indians buy Global Blood Therapeutics Inc. (GBT) shares?

How can I buy Global Blood Therapeutics Inc. (GBT) shares from India?

Can Fractional shares of Global Blood Therapeutics Inc. (GBT) be purchased?

What are the documents required to start investing in Global Blood Therapeutics Inc. (GBT) stocks?

We are a SEBI registered investement advisor